MPXI Labs Cannabis Distillates and Derivative Products for Canadian and Global Markets
A subsidiary of MPX International Corp, MPXI Labs is a Swiss-based producer of legal cannabis and cannabinoid-based formulations, serving both the medical and consumer markets.
Our managing group previously developed MPX Bioceutical Corp. from a sole licensed producer in Canada into one of the leading vertically-integrated and multi-state agents in the US.
Strong team with a proven track record
Our company has assembled an experienced team of specialists with a track record of operational success, as well as the drive to accelerate growth and deliver results to customers, patients and shareholders alike.
We assess all legal markets for the opportunity to grow our diverse portfolio of brands. From hemp pre-rolls to transdermal medical patches, our custom formulation labs and retail stores ensure each adheres to our core values of consistency, reliability and quality.
Fully diversified cultivation operations
Through years of developing cultivation facilities, we apply our expertise and know-how across several continents, cultivating in a range of environments, from automated indoor grows to outdoor farms spanning multiple hectares.
Our focus on cost efficiency ensures we can maintain long-term competitiveness as growers, with the aim to serve both the rapidly evolving consumer market, as well as regulated medical markets, through our fully diversified cultivation operations.
Extraction and formulation
MPXI Labs continues to live up to the MPX reputation for best-in-class cannabis extracts and concentrates. Our standard operating procedures (SOPs) have been developed to highly refined US standards and integrated into our GMP-grade production facilities.
We are implementing high capacity supercritical carbon dioxide (CO₂) and ethanol extraction processes, alongside innovative formulation and distillation equipment.
Our medical brand, Salus BioPharma uses over 90 medical stock-keeping units (SKUs), catering to a diverse range of consumers and patients.
We actively formulate with nine different cannabinoids, taking pride in the guarantee that product quality remains consistent across markets.
Innovative retail experiences
Our goal is to set the bar high in new markets, whether as a platform for our brands or an outlet for third-party brands.
We allow customers to delve into the world of new cannabis and cannabinoid advances through engaging retail experiences and education.
We leverage Canadian and US knowledge across global markets, including Australia, Malta, South Africa, Switzerland and the UK.
Soon, we plan to launch cannabinoid and terpene-infused edibles, beverages and vaporisers to the growing markets we serve.
About MPX International Corp
MPX International is a publicly-listed Canadian cannabis company, formally part of MPX Bioceutical, which sold its US business to iAnthus in an industry-record transaction.
The newly formed company acquired all non-US assets from MPX Bioceutical, which is now building shareholder value through a focus on production, circulation and trading of high-quality cannabis distillates and derivative products for the Canadian and worldwide medical and adult-use cannabis markets.
Since the spinout, MPX International assets include Spartan Wellness, beleaf, Salus BioPharma, Canveda, HolyWeed and Kajeenga.